understand
exposur
viral
bacteri
pathogen
associ
recurr
wheez
increas
asthma
risk
preschoolag
children
determin
popul
risk
develop
asthma
childhood
assess
effect
respiratori
syncyti
viru
rsv
infect
futur
risk
asthma
identifi
patient
would
benefit
rsv
prophylaxi
understand
mechan
allergyviru
interact
associ
allerg
inflamm
asthma
recognit
commerci
support
cme
activ
receiv
extern
commerci
support
list
cme
exam
author
jennif
fergeson
adeeb
bulkhi
md
andrew
cook
md
chen
hsing
lin
md
sultan
alandijani
md
peter
ricketti
richard
f
lockey
md
disclosur
signific
relationship
relev
commerci
companiesorgan
exam
author
disclos
relev
financi
relationship
alon
combin
factor
appear
exert
influenc
within
first
year
life
asthma
becom
establish
child
enter
grade
school
age
year
therefor
allerg
sensit
viral
bacteri
ill
occur
children
asthma
paramount
identifi
genet
environment
factor
activ
interact
andor
direct
immun
system
compon
respiratori
tract
along
pathway
allow
asthma
becom
establish
express
clinic
j
allergi
clin
immunol
key
word
asthma
virus
bacteria
childhood
rhinoviru
respiratori
syncyti
viru
allerg
sensit
inflamm
discuss
articl
jaci
journal
club
blog
wwwjacionlineblogspotcom
variou
environment
risk
factor
demonstr
influenti
incept
childhood
asthma
develop
allerg
sensit
earli
life
follow
wheez
respiratori
tract
ill
caus
infect
variou
respiratori
pathogen
appear
consist
reproduc
shown
allerg
sensit
greatest
effect
recurr
wheez
asthma
process
occur
first
year
life
involv
develop
sensit
multipl
aeroallergen
thu
strength
influenc
appear
binari
quantit
development
natur
preschool
wheez
ill
viral
bacteri
pathogen
also
associ
recurr
wheez
increas
asthma
risk
histor
respiratori
syncyti
viru
rsv
consid
import
respiratori
pathogen
produc
longterm
lower
respiratori
sequela
recent
data
provid
addit
support
relationship
furthermor
anim
studi
provid
mechanist
evid
rsv
caus
asthma
treatment
trial
preterm
infant
palivizumab
antirsv
mab
demonstr
signific
reduct
develop
recurr
wheez
advent
molecular
virolog
technolog
past
decad
human
rhinoviru
increasingli
recogn
major
etiolog
factor
preschool
wheez
ill
highli
signific
link
risk
childhood
asthma
inde
rhinovirusinduc
wheez
ill
associ
approxim
increas
asthma
risk
year
age
potenti
mechan
underli
develop
describ
certain
rhinoviru
speci
eg
c
b
might
virul
therebi
caus
lower
respiratori
tract
ill
increas
morbid
result
emerg
depart
visit
hospit
moreov
develop
recurr
lower
respiratori
tract
symptom
rhinoviru
c
infect
occur
frequent
subject
demonstr
allerg
sensit
airway
bacteria
earli
life
also
influenc
asthma
risk
colon
common
respiratori
pathogen
streptococcu
pneumonia
moraxella
catarrhali
haemophilu
influenza
earli
life
signal
increas
risk
recurr
wheez
earli
childhood
asthma
pathogen
associ
acut
wheez
ill
young
children
new
tool
assess
airway
microbiom
shed
addit
light
relationship
benefici
versu
pathogen
microb
risk
acut
wheez
asthma
articl
expand
contribut
allerg
sensit
viral
bacteri
respiratori
tract
wheez
ill
increas
risk
recurr
preschool
wheez
childhood
asthma
possibl
emphas
data
gener
longterm
longitudin
studi
facilit
etiolog
epidemiolog
character
understand
role
viral
infect
wheez
expand
develop
evolut
molecular
viral
diagnost
result
studi
use
pcr
sequencedbas
test
indic
long
list
virus
caus
upper
lower
respiratori
tract
ill
tabl
clinic
manifest
infect
differ
virus
quit
similar
infect
lead
symptom
cold
symptom
lower
respiratori
syndrom
pneumon
bronchiol
acut
wheez
ill
risk
asthma
seem
close
associ
occurr
frequenc
virusinduc
wheez
ill
clinic
manifest
acut
viral
ill
associ
increas
risk
asthma
includ
fever
pneumon
nearli
wheez
ill
first
year
occur
viral
respiratori
tract
infect
virus
frequent
associ
wheez
ill
rsv
rhinovirus
virus
commonli
detect
wheez
ill
includ
metapneumoviru
coronavirus
parainfluenza
virus
bocavirus
coinfect
viru
commonli
confirm
infant
associ
sever
symptom
prolong
ill
caus
sequenti
infect
viru
infect
viru
follow
bacteri
pathogen
less
commonli
prolong
infect
singl
viru
adenovirus
like
respiratori
virus
caus
prolong
viral
shed
rsv
rsv
envelop
nonseg
negativestrand
rna
viru
famili
paramyxovirida
rsv
infect
ubiquit
infanc
rsv
main
antigen
group
b
gener
rsvb
infect
tend
caus
less
sever
ill
virul
vari
consider
individu
strain
rsv
even
within
antigen
group
rsv
infect
caus
mild
asymptomat
ill
estim
infect
lead
outpati
clinic
visit
less
infect
lead
hospit
even
rsv
infect
common
caus
bronchiol
first
year
life
risk
factor
rsvinduc
bronchiol
includ
prematur
comorbid
condit
affect
heart
lung
immun
system
age
season
birth
peak
age
suscept
rsv
lower
respiratori
tract
infect
month
age
neutral
antibodi
acquir
transplacent
mother
wane
rsv
replic
epitheli
cell
line
upper
airway
bronchiol
type
pneumocyt
rsv
infect
extend
lower
airway
caus
airway
narrow
closur
caus
epitheli
cell
necrosi
induc
cellular
inflamm
mucu
hypersecret
sever
line
evid
suggest
sever
rsv
infect
earli
life
contribut
risk
childhood
asthma
first
approxim
one
third
children
rsvinduc
bronchiol
recurr
wheez
episod
turn
children
recurr
wheez
increas
risk
subsequ
asthma
especi
atop
parent
atop
featur
furthermor
larg
tennesse
medicaid
databas
children
born
approxim
day
peak
rsv
season
increas
risk
bronchiol
correspond
increas
risk
asthma
age
year
similarli
analysi
rsvinduc
bronchiol
birth
cohort
studi
indic
posit
associ
risk
asthma
allerg
sensit
final
analysi
tucson
children
respiratori
cohort
young
adulthood
reveal
interact
rsv
lower
respiratori
tract
infect
infanc
smoke
respect
asthma
activ
smoke
signific
risk
factor
rel
risk
ci
p
asthma
young
adult
histori
rsv
lower
respiratori
tract
infect
infanc
treatment
mab
specif
rsv
f
protein
palivizumab
motavizumab
reduc
risk
rsvinduc
bronchiol
sever
intervent
studi
test
whether
prevent
rsvinduc
bronchiol
infanc
lead
reduct
recurr
wheez
asthma
prospect
nonrandom
studi
palivizumab
administr
preterm
infant
canada
europ
report
found
reduct
risk
recurr
wheez
age
year
nonatop
children
effect
atop
children
multicent
studi
conduct
netherland
healthi
preterm
infant
born
week
gestat
enrol
doubleblind
placebocontrol
trial
palivizumab
prophylaxi
monitor
year
determin
effect
recurr
wheez
palivizumab
treatment
led
rel
reduct
total
number
wheez
day
first
year
life
similarli
casecontrol
studi
palivizumab
japanes
infant
mild
prematur
demonstr
reduc
recurr
wheez
treat
versu
untreat
group
vs
p
recent
studi
evalu
effect
motavizumab
healthi
fullterm
navajo
infant
ethnic
group
high
risk
bronchiol
doubleblind
placebocontrol
random
trial
involv
infant
age
month
less
motavizumab
reduc
rel
risk
hospit
admiss
bronchiol
howev
motavizumab
reduc
subsequ
rate
medic
attend
wheez
age
year
vs
placebo
group
thu
passiv
immun
rsv
certainli
reduc
acut
bronchiol
preterm
infant
like
reduc
rate
recurr
wheez
prematur
infant
whether
rsv
prophylaxi
reduc
recurr
wheez
term
infant
unclear
addit
studi
need
clearli
understand
might
benefit
prophylaxi
reduc
recurr
wheez
also
whether
approach
prevent
atop
asthma
given
children
becom
polysensit
allergen
infanc
greatest
risk
persist
wheez
reduc
lung
function
latter
question
great
clinic
import
rhinovirus
consist
individu
type
classifi
speci
b
c
base
viral
genet
rhinovirus
pathogen
often
associ
upper
respiratori
tract
infect
common
cold
also
caus
lower
respiratori
tract
infect
wheez
ill
second
common
virus
associ
bronchiol
common
virus
detect
associ
wheez
ill
children
age
year
speci
rhinoviru
affect
virul
rhinovirus
c
caus
sever
ill
infant
like
caus
lower
respiratori
ill
cadherinrel
famili
member
recent
identifi
entri
factor
airway
epitheli
cell
rhinoviru
c
interestingli
polymorph
associ
risk
childhood
asthma
risk
allel
associ
cell
surfac
find
suggest
possibl
rhinoviru
c
infect
earli
life
could
contribut
asthma
pathogenesi
year
mistakenli
assum
rhinoviru
infect
confin
upper
airway
assumpt
base
earli
find
rhinovirus
replic
best
thought
higher
temperatur
lower
airway
would
preclud
lower
airway
infect
howev
temperatur
larg
medium
conduct
airway
cooler
core
temperatur
ideal
rhinoviru
replic
furthermor
rhinoviru
type
includ
cspeci
virus
replic
equal
well
final
rhinoviru
detect
sputum
bronchial
biopsi
specimen
experiment
inocul
upper
airway
concurr
peak
symptom
reduct
peak
expiratori
flow
rhinovirus
also
detect
lower
airway
biopsi
specimen
infant
recurr
wheez
find
provid
strong
evid
rhinoviru
infect
lower
airway
especi
young
children
rhinovirusinduc
wheez
ill
first
year
life
close
associ
risk
subsequ
asthma
relationship
first
recogn
longterm
studi
finnish
infant
hospit
acut
wheez
ill
rhinoviru
predomin
viru
detect
wheez
ill
month
age
reassess
year
later
children
wheez
rhinoviru
first
year
life
asthma
similar
find
obtain
subsequ
followup
children
adolesc
birth
cohort
studi
provid
definit
evid
strong
relationship
rhinovirusinduc
wheez
asthma
childhood
origin
asthma
coast
studi
outpati
rhinovirusinduc
wheez
ill
first
year
life
signific
predictor
recurr
wheez
age
year
furthermor
viral
caus
wheez
ill
differenti
affect
risk
subsequ
asthma
risk
asthma
greater
children
wheez
rhinoviru
odd
ratio
children
wheez
rhinoviru
rsv
compar
children
wheez
rsv
similar
find
report
childhood
asthma
studi
perth
earlylif
infect
rhinoviru
rsv
associ
increas
risk
asthma
children
aeroallergen
sensit
year
age
studi
conduct
netherland
rhinovirusinduc
wheez
episod
posit
relat
asthma
risk
relationship
partial
explain
lower
lung
function
infanc
risk
factor
rhinoviru
wheez
final
collabor
studi
involv
birth
cohort
coast
copenhagen
prospect
studi
asthma
childhood
genotyp
strongli
influenc
risk
rhinovirusinduc
wheez
probabl
infant
rhinovirusinduc
wheez
would
go
asthma
thu
unresolv
question
whether
rhinovirusinduc
ill
childhood
promot
develop
asthma
reveal
presenc
preexist
asthma
previou
section
review
inform
link
viral
infect
wheez
ill
subsequ
asthma
remark
associ
airway
bacteria
wheez
ill
might
similarli
robust
relationship
could
begin
quit
earli
life
danish
birth
cohort
studi
colon
nasopharynx
pneumonia
catarrhali
h
influenza
month
age
associ
increas
incid
recurr
wheez
asthma
earli
childhood
viral
infect
lead
chang
composit
airway
microbiom
overgrowth
respiratori
pathogen
like
viru
secondari
chang
airway
bacteria
contribut
respiratori
symptom
perhap
airway
obstruct
find
suggest
potenti
role
antibiot
treatment
wheez
ill
earli
life
howev
evid
base
approach
appear
mix
one
hand
seriou
bacteri
infect
accompani
bronchiol
appear
rare
recent
metaanalysi
found
antibiot
azithromycin
ampicillin
efficaci
treatment
bronchiol
hand
bachari
et
al
conduct
random
multicent
clinic
trial
involv
preschool
children
histori
recurr
wheez
ill
treat
azithromycin
placebo
begin
respiratori
symptom
azithromycin
treatment
reduc
risk
progress
sever
lower
respiratori
ill
hazard
ratio
ci
p
mechan
effect
could
relat
either
antimicrobi
antiinflammatori
activ
macrolid
antibiot
addit
studi
need
clearli
identifi
children
like
respond
azithromycin
therapi
given
risk
select
antibioticresist
organ
theoret
risk
disturb
microbiom
infanc
although
bacteri
pathogen
posit
associ
wheez
asthma
environment
exposur
broad
rang
bacteria
might
protect
wheez
ill
exampl
children
expos
anim
shed
farm
less
like
wheez
earli
life
includ
transient
wheez
presum
viral
origin
benefici
effect
appear
relat
exposur
divers
environment
microb
inde
anim
model
indic
gastrointestin
administr
select
bacteria
provid
protect
sign
ill
challeng
rsv
furthermor
exposur
urban
environ
relat
risk
recurr
wheez
urban
environ
childhood
asthma
birth
cohort
studi
dust
sampl
obtain
first
year
life
analyz
bacteria
allergen
content
infant
wheez
atopi
age
year
like
grow
home
reduc
exposur
microb
specif
allergen
cat
mous
cockroach
find
suggest
earlylif
exposur
bacteria
perhap
anim
protein
modul
immun
respons
import
determin
respiratori
ill
sever
allerg
sensit
notabl
perenni
aeroallergen
defin
pivot
risk
factor
develop
asthma
recent
becom
evid
time
allerg
sensit
quantiti
sensit
import
prognost
indic
simpson
et
al
identifi
atopi
phenotyp
children
term
multipl
earli
sensit
children
sensit
multipl
aeroallergen
earli
age
simpson
et
al
report
remark
increas
risk
asthma
incept
sever
exacerb
lead
hospit
impair
lung
function
link
earlylif
sensit
multipl
allergen
increas
asthma
risk
replic
addit
cohort
studi
observ
link
earli
sensit
aeroallergen
asthma
risk
part
due
synergi
allerg
inflamm
viral
infect
commonli
rhinoviru
inde
children
coast
studi
sensit
aeroallergen
wheez
rhinoviru
first
year
life
greatest
risk
asthma
incept
led
question
whether
viral
ill
earli
life
lead
allerg
sensit
whether
convers
true
use
longitudin
multist
markov
model
coast
studi
jackson
et
al
identifi
sequenti
relationship
wherebi
allerg
sensit
lead
viral
wheez
relationship
strongest
rhinovirusinduc
wheez
evid
viral
wheez
led
sensit
also
strong
evid
implic
allerg
sensit
exposur
risk
factor
wheez
common
cold
infect
later
childhood
emerg
depart
studi
detect
respiratori
tract
viru
commonli
rhinoviru
detect
allergenspecif
ige
andor
presenc
eosinophil
inflamm
identifi
risk
factor
acut
wheez
episod
notabl
viral
infect
allerg
inflamm
synergist
enhanc
risk
wheez
higher
level
allergenspecif
ige
confer
greatest
risk
synerg
might
particularli
notabl
patient
rhinoviru
c
aeroallergen
sensit
recent
report
risk
factor
recurr
sever
exacerb
lead
emerg
depart
visit
hospit
multipl
mechan
viral
infect
thought
interact
allerg
inflamm
lead
lower
respiratori
airway
dysfunct
wheez
asthma
exacerb
first
underli
allerg
inflamm
directli
enhanc
airway
respons
rhinoviru
infect
addit
viral
infect
damag
barrier
function
airway
epithelium
lead
enhanc
absorpt
aeroallergen
across
airway
wall
enhanc
inflamm
wherea
underli
allerg
inflamm
might
also
lead
enhanc
viral
replic
interest
rhinoviru
infect
allergen
enhanc
airway
epitheli
cell
product
recent
identifi
innat
cytokin
promot
type
airway
inflamm
remodel
steroidresist
pathway
report
upregul
children
difficulttocontrol
asthma
interestingli
polymorph
link
intermedi
lateonset
wheez
strongli
link
earlylif
allerg
sensit
anoth
innat
epitheli
cytokin
also
induc
rhinoviru
like
accentu
allerg
airway
inflamm
context
rhinoviru
infect
allerg
subject
final
signific
evid
children
allerg
asthma
impair
antivir
respons
inde
allergen
exposur
highaffin
ige
receptor
crosslink
shown
impair
virusinduc
type
iii
interferon
product
peripher
blood
cell
fig
result
would
enhanc
viral
replic
enhanc
type
inflamm
airway
direct
evid
support
import
allergenviru
interact
patient
virusinduc
wheez
asthma
exacerb
come
recent
clinic
trial
omalizumab
antiig
prevent
season
virusinduc
asthma
exacerb
trial
virusinduc
exacerb
significantli
reduc
omalizumab
reduct
coincid
enhanc
type
interferon
respons
ex
vivo
rhinovirusstimul
mononuclear
cell
note
particip
larger
increas
type
interferon
respons
omalizumab
treatment
greatest
protect
virusinduc
exacerb
two
key
risk
factor
develop
childhood
asthma
develop
allerg
sensit
earli
life
wheez
respiratori
tract
ill
caus
primarili
virus
also
bacteria
either
alon
coinfect
accompani
ill
viral
caus
therapi
direct
risk
factor
either
alon
combin
appear
essenti
compon
target
develop
effect
strategi
primari
prevent
asthma
children
earlylif
aeroallergen
sensit
viral
wheez
ill
independ
synergist
risk
factor
asthma
incept
interplay
antivir
respons
normal
airway
plasmacytoid
dendrit
cell
pdc
major
sourc
type
type
iii
interferon
respons
viral
infect
cell
also
lowlevel
express
context
allergi
pdc
express
greater
invers
relat
interferon
respons
addit
crosslink
reduc
interferon
respons
consequ
suppress
interferon
respons
viral
infect
could
includ
increas
viral
replic
sever
ill
wheez
exacerb
preexist
asthma
